Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
作者更正:紫杉醇联合卡铂和度伐利尤单抗,加或不加oleclumab,用于治疗既往未接受治疗的局部晚期或转移性三阴性乳腺癌女性患者:SYNERGY I/II期随机试验
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-023-44071-8
Buisseret, Laurence; Loirat, Delphine; Aftimos, Philippe; Maurer, Christian; Punie, Kevin; Debien, Véronique; Kristanto, Paulus; Eiger, Daniel; Goncalves, Anthony; Ghiringhelli, François; Taylor, Donatienne; Clatot, Florent; Van den Mooter, Tom; Ferrero, Jean-Marc; Bonnefoi, Hervé; Canon, Jean-Luc; Duhoux, Francois P; Mansi, Laura; Poncin, Renaud; Barthélémy, Philippe; Isambert, Nicolas; Denis, Zoë; Catteau, Xavier; Salgado, Roberto; Agostinetto, Elisa; de Azambuja, Evandro; Rothé, Françoise; Craciun, Ligia; Venet, David; Romano, Emanuela; Stagg, John; Paesmans, Marianne; Larsimont, Denis; Sotiriou, Christos; Ignatiadis, Michail; Piccart-Gebhart, Martine